DMD Development Landscape Shifts After Prosensa Failure; Sarepta Continues Strong
Executive Summary
The race to get a Duchenne muscular dystrophy drug to market has been closely watched by investors; new developments in drugs by Prosensa and Sarepta have created an unexpected change in the landscape of treatment development.
You may also be interested in...
Duchenne Muscular Dystrophy Approval Race: BioMarin Pulls Back Into Lead
FDA advisory committee reviews for BioMarin’s drisapersen and Sarepta’s eteplirsen, once eyed as back-to-back meetings, are now set months apart. Draft guidance may help firms overcome previous findings of inadequate data.
Duchenne Muscular Dystrophy: Pipeline And Partnering Snapshot
A full pipeline of symptomatic and disease-modifying treatments for Duchenne will transform a long dormant orphan market into a hotly contested commercial prize. But some issues, foremost the scarcity of trial patients, threaten to stall progress in the field.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.